Early GI Involvement Predictive of Scleroderma Outcomes Rheumatology has published a cohort study showing that earlyGI symptoms and overall symptom burden predict both GI progression and mortality in Systemic Sclerosis (SSc). https://t.co/ftz6TeZv5Z https://t.co/Nw3wQ06VTq

NEW FROM ACR: Clinical responses with an IL-23i in patients with active PsA See the efficacy and safety data through ~5 years in the RheumNow poster hall. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/jejeZwo6is https://t.co/fuF3j3eO0S

Immune-Mediated Inflammatory Diseases Following Uveitis A Korean insurance claims data study showed children and adolescents diagnosed with uveitis have a 7-fold increased risk of developing an immune-mediated inflammatory disorder (IMID). https://t.co/NJI4369ygL https://t.co/6mHK8hYMeG

HCQ: 5 mg/kg/day Is Only the Starting Point HCQ is one of the most important drugs in rheumatology, especially for SLE. It reduces flares, organ damage, cardiovascular events, and pregnancy complications, and it improves survival. Yet many clinicians still prescribe HCQ as if https://t.co/Fwr92tuZf2

Does Exercise and Lifestyle Modification Improve RA? Do exercise or lifestyle modifications reduce the risk of getting RA or change those with early RA? A current review and meta-analysis found no studies addressing the benefit in pre-clinical RA, but found evidence that https://t.co/Bvp3Ery5Fg

Does RTX work in CNS lupus? Japanese experience in 17 refractory NP-SLE pts Rx w/ RTX - 16/17 had significant improve. & 1 partial improvement -- none had NP-SLE relapse. Two died during COVID> https://t.co/GpCgpSxn37 https://t.co/PMz05MHBhj

Press release of early study of IMVT-1402 (human mAb targeting FcRn) Open-label Rx in 170 active, refractory RA showed ACR 20/50/70 of 73%/54%/36% at wk 16. Next, Responders will do a blinded withdrawl - blinded results to follow. https://t.co/Mzmb3PPvMF https://t.co/oZ99l9VJQU

NLRP3 inflammasome activation triggers PAD (2, 4) release from human neutrophils, increasing citrullination of intracellular proteins (CCPs) and driving the pathogenesis of #RA. Further proof: , PAD concentrations and PAD activity correlate with IL-1β.https://t.co/pRQy0ECG5d https://t.co/SlLO35JhvY

RheumNow’s global faculty reporters help translate the data into clinical practice. Featuring: ✨ Dr. Janet Pope (@Janetbirdope) ✨ Dr. Yuz Yusof (@Yuz6Yusof) ✨ Dr. Jiha Lee (@JihaRheum) ✨ Dr. Mrinalini Dey (@DrMiniDey) ✨ Dr. Aurelie Najm (@AurelieRheumo) ✨ Dr. Bella https://t.co/0Pm0uUwRNf

Kissei Pharmaceuticals announced 20 deaths related to receiving avacopan (Tavneos), a vasculitis drug sold by the firm in Japan. Drug was released in June 2022, since its been given to ~8,500 pts. Avacopan safety is being reviewed by FDA with Amgen. https://t.co/ri0nROCL5U https://t.co/jbksrWMFwI

FDA has approved a dosing update for burosumab-twza (Crysvita, Kyowa Kirin) to allow for increased dose and frequency when needed in adults with X-linked hypophosphatemia (XLH). https://t.co/EPyp6tDsaf https://t.co/1HEaQRk9BR